Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc. (Nasdaq: PWUP) filed an 8-K current report with the Securities and Exchange Commission on September 9, 2026, marking a material disclosure event for the blank-check company focused on the biopharmaceutical and life sciences sector. Originally organized as a special purpose acquisition company, PWUP has pursued targets within healthcare, with its corporate evolution reflected in the Aspire Biopharma Holdings name now associated with the ticker. The 8-K accession number 0001493152-26-041918 captures the latest chapter of the company's public lifecycle, which spans deal-structuring activity characteristic of the post-2020 SPAC wave in health-focused vehicles. Visit SpacDesk and sign up for full access to explore PWUP's complete filing history, sponsor details, deal timeline, and real-time status updates.